Advertisement

Im Focus Onkologie

, Volume 21, Issue 5, pp 16–18 | Cite as

Metastasiertes Prostatakarzinom

Die radikale Prostatektomie als Teil der multimodalen Therapie

  • Michael Chaloupka
  • Annika Herlemann
  • Christian Gratzke
  • Christian Stief
Uroonkologie Fortbildung
  • 52 Downloads

Lange Zeit war die radikale Prostatektomie keine Option zur Therapie des metastasierten Prostatakarzinoms. Es gibt aber immer mehr Hinweise, dass gut selektierte Patienten mit diesen Tumoren davon profitieren können. In den kommenden Jahren werden Ergebnisse aus randomisiert-kontrollierten Studien die Rolle der radikalen Prostatektomie als Teil der multimodalen Behandlung des metastasierten Prostatakarzinoms besser charakterisieren.

Literatur

  1. 1.
    Herlemann A, Stief CG. [Active surveillance for low-risk prostate cancer]. Urologe A. 2016;55(2):269–81.CrossRefPubMedGoogle Scholar
  2. 2.
    Spek A et al. [Radical prostatectomy as part of a multimodal concept for patients with prostate cancer and bone metastases at initial diagnosis]. Urologe A. 2017;56(5):595–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Stattin P et al. Prostate Cancer Registries: Current Status and Future Directions. Eur Urol 2015; 68(5): e110.CrossRefPubMedGoogle Scholar
  4. 4.
    Cornford P et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol. 2017;71(4): 630–42.CrossRefGoogle Scholar
  5. 5.
    Attard G et al. Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial. Eur Urol. 2014;66(5):799–802.CrossRefPubMedGoogle Scholar
  6. 6.
    James ND et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024): 1163–77.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Ljungberg B et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015; 67(5):913–24.CrossRefGoogle Scholar
  8. 8.
    Haffner MC et al. Tracking the clonal origin of lethal prostate cancer. J Clin Invest. 2013;123(11):4918–22.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Engel J et al. Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol. 2010;57(5):754–61.CrossRefPubMedGoogle Scholar
  10. 10.
    Steuber T et al. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study. BJU Int. 2011;107(11):1755–61.CrossRefPubMedGoogle Scholar
  11. 11.
    Culp SH et al. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol. 2014;65(6):1058–66.CrossRefPubMedGoogle Scholar
  12. 12.
    Faiena I et al. Cytoreductive prostatectomy: evidence in support of a new surgical paradigm (Review). Int J Oncol. 2014; 45(6):2193–8.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Wenter V et al. Radium-223 for primary bone metastases in patients with hormonesensitive prostate cancer after radical prostatectomy. Oncotarget. 2017;8(27): 44131–40.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Sooriakumaran P et al. A Multi-institutional Analysis of Perioperative Outcomes in 106 Men Who Underwent Radical Prostatectomy for Distant Metastatic Prostate Cancer at Presentation. Eur Urol. 2016;69(5): 788–94.CrossRefPubMedGoogle Scholar
  15. 15.
    Ost P et al. Prognostic factors influencing prostate cancer-specific survival in noncastrate patients with metastatic prostate cancer. Prostate. 2014;74(3): 297–305.CrossRefPubMedGoogle Scholar
  16. 16.
    Schweizer MT et al. Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy. Ann Oncol. 2013;24(11):2881–6.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8(6):378–82.CrossRefGoogle Scholar
  18. 18.
    Sooriakumaran P et al. Testing radical prostatectomy in men with prostate cancer and oligometastases to the bone. ISRCTN. 2017 [cited 2017 Jul 12]. Available from: http://www.isrctn.com/ISRCTN15704862, doi: https://10.1186/ISRCTN15704862.
  19. 19.
    Chapin BF et al. Best systemic therapy or Best systemic therapy (BST) plus definitive treatment (Radiation or Surgery). Clinical Trials. 2017 [cited 2017 Jul 12]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01751438.
  20. 20.
    Martini-Klinik [Internet]. Hamburg: Martini-Klinik [cited 2017 Jul 12]. g-RAMPP-Studie für Patienten mit neu diagnostiziertem, ossär metastasiertem Prostatakarzinom und eingeschränkter Tumorlast. Available from: https://www.martini-klinik.de/fuer-aerzte/studien/studienuebersicht/g-rampp-studie/

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  • Michael Chaloupka
    • 1
  • Annika Herlemann
    • 2
  • Christian Gratzke
    • 2
  • Christian Stief
    • 2
  1. 1.Urologische Klinik und PoliklinikKlinikum der Ludwig-Maximilians-Universität München, Campus GroßhadernMünchenDeutschland
  2. 2.

Personalised recommendations